A four-month sales contribution from the Upsher-Smith generics business in the US has helped to boost Sawai’s turnover by 15% for the first nine months of its financial year ending 31 March 2018, according to the latest figures published by the Japanese firm.
“With the Japanese generics market as a whole growing at a slower pace, and sales of contract manufacturing down from the prior year, sales in Japan grew by just 1.6%,” Sawai pointed out, taking its domestic sales to ¥103 billion (US$968 million) for the nine-month period. However, “overall sales grew by 15.0% thanks to the inclusion of the June to September sales of Upsher-Smith Laboratories” following Sawai’s US$1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
